# Deniz Kirik

List of Publications by Year
in descending order



| | | | |
|---|---|---|---|
| 132 papers | 14,336 citations | 19657<br>61 h-index | 19749<br>117 g-index |
| 136 all docs | 136 docs citations | 136 times ranked | 12531 citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | A combined cell and gene therapy approach for homotopic reconstruction of midbrain dopamine pathways using human pluripotent stem cells. Cell Stem Cell, 2022, 29, 434-448.e5. | 11.1 | 23 |
| 2 | Viral-based rodent and nonhuman primate models of multiple system atrophy: Fidelity to the human disease. Neurobiology of Disease, 2021, 148, 105184. | 4.4 | 14 |
| 3 | Effects of mutant huntingtin inactivation on Huntington diseaseâ€related behaviours in the BACHD mouse model. Neuropathology and Applied Neurobiology, 2021, 47, 564-578. | 3.2 | 1 |
| 4 | Positive symptom phenotypes appear progressively in â€œEDiPSâ€, a new animal model of the schizophrenia prodrome. Scientific Reports, 2021, 11, 4294. | 3.3 | 6 |
| 5 | Comparison of Locus Coeruleus Pathology with Nigral and Forebrain Pathology in Parkinson's Disease. Movement Disorders, 2021, 36, 2085-2093. | 3.9 | 23 |
| 6 | DNAJB6 suppresses alpha-synuclein induced pathology in an animal model of Parkinson's disease. Neurobiology of Disease, 2021, 158, 105477. | 4.4 | 14 |
| 7 | Two C-terminal sequence variations determine differential neurotoxicity between human and mouse Î±-synuclein. Molecular Neurodegeneration, 2020, 15, 49. | 10.8 | 6 |
| 8 | Viral Delivery of GDNF Promotes Functional Integration of Human Stem Cell Grafts in Parkinsonâ€™s Disease. Cell Stem Cell, 2020, 26, 511-526.e5. | 11.1 | 56 |
| 9 | How is alphaâ€synuclein cleared from the cell?. Journal of Neurochemistry, 2019, 150, 577-590. | 3.9 | 113 |
| 10 | Enhanced Dopamine in Prodromal Schizophrenia (EDiPS): a new animal model of relevance to schizophrenia. NPJ Schizophrenia, 2019, 5, 6. | 3.6 | 15 |
| 11 | Organotypic slice culture model demonstrates inter-neuronal spreading of alpha-synuclein aggregates. Acta Neuropathologica Communications, 2019, 7, 213. | 5.2 | 45 |
| 12 | A44â€…Analysis of the deletion of mutant huntingtin from A2A-receptor expressing neurons. , 2018, , . | | 0 |
| 13 | Quantification of Total and Mutant Huntingtin Protein Levels in Biospecimens Using a Novel alphaLISA Assay. ENeuro, 2018, 5, ENEURO.0234-18.2018. | 1.9 | 10 |
| 14 | Longitudinal monoaminergic PET imaging of chronic proteasome inhibition in minipigs. Scientific Reports, 2018, 8, 15715. | 3.3 | 12 |
| 15 | In vivo quantification of glial activation in minipigs overexpressing human Î±â€synuclein. Synapse, 2018, 72, e22060. | 1.2 | 15 |
| 16 | Toxic effects of human and rodent variants of alphaâ€synuclein <i>inÂvivo</i>. European Journal of Neuroscience, 2017, 45, 536-547. | 2.6 | 21 |
| 17 | Novel oligodendroglial alpha synuclein viral vector models of multiple system atrophy: studies in rodents and nonhuman primates. Acta Neuropathologica Communications, 2017, 5, 47. | 5.2 | 33 |
| 18 | Gene therapy for Parkinson's disease: Disease modification by GDNF family of ligands. Neurobiology of Disease, 2017, 97, 179-188. | 4.4 | 40 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Interaction between subclinical doses of the Parkinsonâ€™s disease associated gene, Î± -synuclein , and the pesticide, rotenone, precipitates motor dysfunction and nigrostriatal neurodegeneration in rats. Behavioural Brain Research, 2017, 316, 160-168. | 2.2 | 19 |
| 20 | Preserved Function of Afferent Parvalbumin-Positive Perisomatic Inhibitory Synapses of Dentate Granule Cells in Rapidly Kindled Mice. Frontiers in Cellular Neuroscience, 2017, 11, 433. | 3.7 | 8 |
| 21 | Assessment of brain metabolite correlates of adenoâ€associated virusâ€mediated overâ€expression of human alphaâ€synuclein in cortical neurons by <i>inÂvivo</i><sup>1</sup>Hâ€<scp>MR</scp> spectroscopy at 9.4 T. Journal of Neurochemistry, 2016, 137, 806-819. | 3.9 | 3 |
| 22 | A novel multiplex assay for simultaneous quantification of total and S129 phosphorylated human alpha-synuclein. Molecular Neurodegeneration, 2016, 11, 61. | 10.8 | 39 |
| 23 | How can <scp>rAAV</scp>â€Î±â€synuclein and the fibril Î±â€synuclein models advance our understanding of Parkinson's disease?. Journal of Neurochemistry, 2016, 139, 131-155. | 3.9 | 84 |
| 24 | Overexpression of Î±-synuclein in oligodendrocytes does not increase susceptibility to focal striatal excitotoxicity. BMC Neuroscience, 2015, 16, 86. | 1.9 | 5 |
| 25 | Selective loss of oxytocin and vasopressin in the hypothalamus in early <scp>H</scp>untington disease: a case study. Neuropathology and Applied Neurobiology, 2015, 41, 843-848. | 3.2 | 31 |
| 26 | Volumetric Analysis of the Hypothalamus in Huntington Disease Using 3T MRI: The IMAGE-HD Study. PLoS ONE, 2015, 10, e0117593. | 2.5 | 30 |
| 27 | Controlled Striatal DOPA Production From a Gene Delivery System in a Rodent Model of Parkinson's Disease. Molecular Therapy, 2015, 23, 896-906. | 8.2 | 18 |
| 28 | Ser129 phosphorylation of endogenous Î±-synuclein induced by overexpression of polo-like kinases 2 and 3 in nigral dopamine neurons is not detrimental to their survival and function. Neurobiology of Disease, 2015, 78, 100-114. | 4.4 | 24 |
| 29 | Differential Dopamine Receptor Occupancy Underlies L-DOPA-Induced Dyskinesia in a Rat Model of Parkinson's Disease. PLoS ONE, 2014, 9, e90759. | 2.5 | 16 |
| 30 | Global Optogenetic Activation of Inhibitory Interneurons during Epileptiform Activity. Journal of Neuroscience, 2014, 34, 3364-3377. | 3.6 | 103 |
| 31 | Hippocampal Lewy pathology and cholinergic dysfunction are associated with dementia in Parkinsonâ€™s disease. Brain, 2014, 137, 2493-2508. | 7.6 | 232 |
| 32 | Optogenetic inhibition of chemically induced hypersynchronized bursting in mice. Neurobiology of Disease, 2014, 65, 133-141. | 4.4 | 44 |
| 33 | Twisting mice move the dystonia field forward. Journal of Clinical Investigation, 2014, 124, 2848-2850. | 8.2 | 1 |
| 34 | Animal models of Parkinson's disease: Limits and relevance to neuroprotection studies. Movement Disorders, 2013, 28, 61-70. | 3.9 | 156 |
| 35 | Ser129D mutant alpha-synuclein induces earlier motor dysfunction while S129A results in distinctive pathology in a rat model of Parkinson's disease. Neurobiology of Disease, 2013, 56, 47-58. | 4.4 | 42 |
| 36 | Variability in neuronal expression of dopamine receptors and transporters in the substantia nigra. Movement Disorders, 2013, 28, 1351-1359. | 3.9 | 20 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | Boosting chaperone-mediated autophagy in vivo mitigates Î±-synuclein-induced neurodegeneration. Brain, 2013, 136, 2130-2146. | 7.6 | 175 |
| 38 | Trophic factors differentiate dopamine neurons vulnerable to Parkinson's disease. Neurobiology of Aging, 2013, 34, 873-886. | 3.1 | 44 |
| 39 | The behavioural and neuropathological impact of intranigral AAV-Î±-synuclein is exacerbated by systemic infusion of the Parkinson's disease-associated pesticide, rotenone, in rats. Behavioural Brain Research, 2013, 243, 6-15. | 2.2 | 26 |
| 40 | Development of <scp>NMR</scp> spectroscopic methods for dynamic detection of acetylcholine synthesis by choline acetyltransferase in hippocampal tissue. Journal of Neurochemistry, 2013, 124, 336-346. | 3.9 | 8 |
| 41 | Hypothalamic expression of mutant huntingtin contributes to the development of depressive-like behavior in the BAC transgenic mouse model of Huntington's disease. Human Molecular Genetics, 2013, 22, 3485-3497. | 2.9 | 67 |
| 42 | LAMP2A as a therapeutic target in Parkinson disease. Autophagy, 2013, 9, 2166-2168. | 9.1 | 41 |
| 43 | Continuous DOPA synthesis from a single AAV: dosing and efficacy in models of Parkinson's disease. Scientific Reports, 2013, 3, 2157. | 3.3 | 19 |
| 44 | Characterization of Cognitive Deficits in Rats Overexpressing Human Alpha-Synuclein in the Ventral Tegmental Area and Medial Septum Using Recombinant Adeno-Associated Viral Vectors. PLoS ONE, 2013, 8, e64844. | 2.5 | 21 |
| 45 | Design of a Single AAV Vector for Coexpression of TH and GCH1 to Establish Continuous DOPA Synthesis in a Rat Model of Parkinson's Disease. Molecular Therapy, 2012, 20, 1315-1326. | 8.2 | 27 |
| 46 | Î±-Synuclein expression and Nrf2 deficiency cooperate to aggravate protein aggregation, neuronal death and inflammation in early-stage Parkinson's disease. Human Molecular Genetics, 2012, 21, 3173-3192. | 2.9 | 228 |
| 47 | Key factors determining the efficacy of gene therapy for continuous DOPA delivery in the Parkinsonian brain. Neurobiology of Disease, 2012, 48, 222-227. | 4.4 | 8 |
| 48 | Introduction. Neurobiology of Disease, 2012, 48, 151-152. | 4.4 | 3 |
| 49 | Selective neuroprotective effects of the S18Y polymorphic variant of UCH-L1 in the dopaminergic system. Human Molecular Genetics, 2012, 21, 874-889. | 2.9 | 34 |
| 50 | GIRK2 expression in dopamine neurons of the substantia nigra and ventral tegmental area. Journal of Comparative Neurology, 2012, 520, 2591-2607. | 1.6 | 76 |
| 51 | Dysregulated dopamine storage increases the vulnerability to Î±-synuclein in nigral neurons. Neurobiology of Disease, 2012, 47, 367-377. | 4.4 | 53 |
| 52 | Altered profile of basket cell afferent synapses in hyperâ€excitable dentate gyrus revealed by optogenetic and twoâ€pathway stimulations. European Journal of Neuroscience, 2012, 36, 1971-1983. | 2.6 | 15 |
| 53 | Characterization of a rat model of Huntingtonâ€™s disease based on targeted expression of mutant <i>huntingtin</i> in the forebrain using adenoâ€associated viral vectors. European Journal of Neuroscience, 2012, 36, 2789-2800. | 2.6 | 11 |
| 54 | Development of advanced therapies based on viral vector-mediated overexpression of therapeutic molecules and knockdown of disease-related genes for Parkinsonâ€™s disease. Therapeutic Delivery, 2011, 2, 37-50. | 2.2 | 4 |

| # | Article | IF | Citations |
|---|---|---|---|
| 55 | Mutant Huntingtin Causes Metabolic Imbalance by Disruption of Hypothalamic Neurocircuits. Cell Metabolism, 2011, 13, 428-439. | 16.2 | 90 |
| 56 | GDNF fails to exert neuroprotection in a rat Â-synuclein model of Parkinson's disease. Brain, 2011, 134, 2302-2311. | 7.6 | 157 |
| 57 | Changes in key hypothalamic neuropeptide populations in Huntington disease revealed by neuropathological analyses. Acta Neuropathologica, 2010, 120, 777-788. | 7.7 | 93 |
| 58 | Early changes in the hypothalamic region in prodromal Huntington disease revealed by MRI analysis. Neurobiology of Disease, 2010, 40, 531-543. | 4.4 | 74 |
| 59 | A General Chemical Method to Regulate Protein Stability in the Mammalian Central Nervous System. Chemistry and Biology, 2010, 17, 981-988. | 6.0 | 313 |
| 60 | Coâ€expression of Câ€terminal truncated alphaâ€synuclein enhances fullâ€length alphaâ€synucleinâ€induced pathology. European Journal of Neuroscience, 2010, 32, 409-422. | 2.6 | 90 |
| 61 | Microglia Acquire Distinct Activation Profiles Depending on the Degree of Î±-Synuclein Neuropathology in a rAAV Based Model of Parkinson's Disease. PLoS ONE, 2010, 5, e8784. | 2.5 | 207 |
| 62 | Presynaptic dopaminergic compartment determines the susceptibility to L-DOPAâ€"induced dyskinesia in rats. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 13159-13164. | 7.1 | 48 |
| 63 | Optimized adeno-associated viral vector-mediated striatal DOPA delivery restores sensorimotor function and prevents dyskinesias in a model of advanced Parkinsonâ€™s disease. Brain, 2010, 133, 496-511. | 7.6 | 42 |
| 64 | The A9 dopamine neuron component in grafts of ventral mesencephalon is an important determinant for recovery of motor function in a rat model of Parkinsonâ€™s disease. Brain, 2010, 133, 482-495. | 7.6 | 125 |
| 65 | Differential Transduction Following Basal Ganglia Administration of Distinct Pseudotyped AAV Capsid Serotypes in Nonhuman Primates. Molecular Therapy, 2010, 18, 579-587. | 8.2 | 82 |
| 66 | Viral vector-mediated overexpression of Î±-synuclein as a progressive model of Parkinsonâ€™s disease. Progress in Brain Research, 2010, 184, 89-111. | 1.4 | 99 |
| 67 | Adeno-associated viral vector serotypes 1 and 5 targeted to the neonatal rat and pig striatum induce widespread transgene expression in the forebrain. Experimental Neurology, 2010, 222, 70-85. | 4.1 | 23 |
| 68 | Feasibility of in vivo15N MRS detection of hyperpolarized 15N labeled choline in rats. Physical Chemistry Chemical Physics, 2010, 12, 5818. | 2.8 | 96 |
| 69 | Positron Emission Tomography Imaging Demonstrates Correlation between Behavioral Recovery and Correction of Dopamine Neurotransmission after Gene Therapy. Journal of Neuroscience, 2009, 29, 1544-1553. | 3.6 | 32 |
| 70 | Huntingtonâ€™s Disease â€" New Perspectives Based on Neuroendocrine Changes in Rodent Models. Neurodegenerative Diseases, 2009, 6, 154-164. | 1.4 | 25 |
| 71 | Dose Optimization for Long-term rAAV-mediated RNA Interference in the Nigrostriatal Projection Neurons. Molecular Therapy, 2009, 17, 1574-1584. | 8.2 | 67 |
| 72 | Gene Therapy for Dopamine Replacement in ParkinsonÂ´s Disease. Science Translational Medicine, 2009, 1, 2ps2. | 12.4 | 29 |

| # | Article | IF | Citations |
|---|---|---|---|
| 73 | Reconstruction of the nigrostriatal dopamine pathway in the adult mouse brain. European Journal of Neuroscience, 2009, 30, 625-638. | 2.6 | 116 |
| 74 | Optimization of continuous <i>in vivo</i> DOPA production and studies on ectopic DA synthesis using rAAV5 vectors in Parkinsonian rats. Journal of Neurochemistry, 2009, 111, 355-367. | 3.9 | 14 |
| 75 | Proton NMR of <sup>15</sup>N-Choline Metabolites Enhanced by Dynamic Nuclear Polarization. Journal of the American Chemical Society, 2009, 131, 16014-16015. | 13.7 | 107 |
| 76 | Myeloid and lymphoid contribution to non-haematopoietic lineages through irradiation-induced heterotypic cell fusion. Nature Cell Biology, 2008, 10, 584-592. | 10.3 | 143 |
| 77 | In vivo gene delivery to proliferating cells in the striatum generated in response to a 6-hydroxydopamine lesion of the nigro-striatal dopamine pathway. Neurobiology of Disease, 2008, 30, 343-352. | 4.4 | 5 |
| 78 | Serotoninâ€“dopamine interaction in the induction and maintenance of L-DOPA-induced dyskinesias. Progress in Brain Research, 2008, 172, 465-478. | 1.4 | 110 |
| 79 | Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia. Brain, 2008, 131, 3380-3394. | 7.6 | 223 |
| 80 | Impact of grafted serotonin and dopamine neurons on development of L-DOPA-induced dyskinesias in parkinsonian rats is determined by the extent of dopamine neuron degeneration. Brain, 2008, 132, 319-335. | 7.6 | 90 |
| 81 | Functional Convergence of Dopaminergic and Cholinergic Input Is Critical for Hippocampus-Dependent Working Memory. Journal of Neuroscience, 2008, 28, 7797-7807. | 3.6 | 62 |
| 82 | Future Cell- and Gene-Based Therapies for Parkinson's Disease. , 2008, , 145-156. | | 0 |
| 83 | Applications of Lentiviral Vectors for Biology and Gene Therapy of Neurological Disorders. Current Gene Therapy, 2008, 8, 461-473. | 2.0 | 139 |
| 84 | Long-term consequences of human alpha-synuclein overexpression in the primate ventral midbrain. Brain, 2007, 130, 799-815. | 7.6 | 186 |
| 85 | Murine models of acute neuronopathic Gaucher disease. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 17483-17488. | 7.1 | 160 |
| 86 | The Functional Impact of the Intrastriatal Dopamine Neuron Grafts in Parkinsonian Rats Is Reduced with Advancing Disease. Journal of Neuroscience, 2007, 27, 5849-5856. | 3.6 | 33 |
| 87 | Serotonin Neuron Transplants Exacerbate l-DOPA- Induced Dyskinesias in a Rat Model of Parkinson's Disease. Journal of Neuroscience, 2007, 27, 8011-8022. | 3.6 | 180 |
| 88 | Brain area, age and viral vector-specific glial cell-line-derived neurotrophic factor expression and transport in rat. NeuroReport, 2007, 18, 845-850. | 1.2 | 12 |
| 89 | Restoration of the Striatal Dopamine Synthesis for Parkinsons Disease:Viral Vector-Mediated Enzyme Replacement Strategy. Current Gene Therapy, 2007, 7, 109-120. | 2.0 | 45 |
| 90 | Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in parkinsonian rats. Brain, 2007, 130, 1819-1833. | 7.6 | 569 |

| # | Article | IF | Citations |
|---|---|---|---|
| 91 | Seizure Suppression by GDNF Gene Therapy in Animal Models of Epilepsy. Molecular Therapy, 2007, 15, 1106-1113. | 8.2 | 87 |
| 92 | Targetedin uterodelivery of a retroviral vector for gene transfer in the rodent brain. European Journal of Neuroscience, 2006, 24, 1897-1906. | 2.6 | 10 |
| 93 | An investigation of the problem of two-layered immunohistochemical staining in paraformaldehyde fixed sections. Journal of Neuroscience Methods, 2006, 158, 64-74. | 2.5 | 20 |
| 94 | Graft placement and uneven pattern of reinnervation in the striatum is important for development of graft-induced dyskinesia. Neurobiology of Disease, 2006, 21, 657-668. | 4.4 | 105 |
| 95 | Ventral tegmental area dopamine neurons are resistant to human mutant alpha-synuclein overexpression. Neurobiology of Disease, 2006, 23, 522-532. | 4.4 | 89 |
| 96 | Viral Vector Mediated Overexpression of Human Î±-Synuclein in the Nigrostriatal Dopaminergic Neurons: A New Model for Parkinson's Disease. CNS Spectrums, 2005, 10, 235-244. | 1.2 | 31 |
| 97 | Isolation and characterization of neural precursor cells from theSox1-GFP reporter mouse. European Journal of Neuroscience, 2005, 22, 1555-1569. | 2.6 | 53 |
| 98 | Functional properties and synaptic integration of genetically labelled dopaminergic neurons in intrastriatal grafts. European Journal of Neuroscience, 2005, 21, 2793-2799. | 2.6 | 35 |
| 99 | Imaging in cell-based therapy for neurodegenerative diseases. European Journal of Nuclear Medicine and Molecular Imaging, 2005, 32, S417-S434. | 6.4 | 16 |
| 100 | Continuous Low-Level Glial Cell Line-Derived Neurotrophic Factor Delivery Using Recombinant Adeno-Associated Viral Vectors Provides Neuroprotection and Induces Behavioral Recovery in a Primate Model of Parkinson's Disease. Journal of Neuroscience, 2005, 25, 769-777. | 3.6 | 212 |
| 101 | Reversal of dyskinesias in an animal model of Parkinson's disease by continuous L-DOPA delivery using rAAV vectors. Brain, 2005, 128, 559-569. | 7.6 | 74 |
| 102 | Histological analysis of fetal dopamine cell suspension grafts in two patients with Parkinson's disease gives promising results. Brain, 2005, 128, 1478-1479. | 7.6 | 9 |
| 103 | Lentiviral gene delivery of GDNF into the striatum of R6/2 Huntington mice fails to attenuate behavioral and neuropathological changes. Experimental Neurology, 2005, 193, 65-74. | 4.1 | 45 |
| 104 | Cell transplantation in Parkinson's disease: how can we make it work?. Trends in Neurosciences, 2005, 28, 86-92. | 8.6 | 249 |
| 105 | Identification of Dopaminergic Neurons of Nigral and Ventral Tegmental Area Subtypes in Grafts of Fetal Ventral Mesencephalon Based on Cell Morphology, Protein Expression, and Efferent Projections. Journal of Neuroscience, 2005, 25, 6467-6477. | 3.6 | 212 |
| 106 | Overexpression of Glial Cell Line-Derived Neurotrophic Factor Using a Lentiviral Vector Induces Time- and Dose-Dependent Downregulation of Tyrosine Hydroxylase in the Intact Nigrostriatal Dopamine System. Journal of Neuroscience, 2004, 24, 6437-6445. | 3.6 | 140 |
| 107 | Dissociation between short-term increased graft survival and long-term functional improvements in Parkinsonian rats overexpressing glial cell line-derived neurotrophic factor. European Journal of Neuroscience, 2004, 20, 3121-3130. | 2.6 | 25 |
| 108 | Localized striatal delivery of GDNF as a treatment for Parkinson disease. Nature Neuroscience, 2004, 7, 105-110. | 14.8 | 262 |

| # | Article | IF | Citations |
|---|---|---|---|
| 109 | Regulated Delivery of Glial Cell Line-Derived Neurotrophic Factor into Rat Striatum, Using a Tetracycline-Dependent Lentiviral Vector. Human Gene Therapy, 2004, 15, 934-944. | 2.7 | 96 |
| 110 | Adult Bone Marrow-Derived Cell Fusion with Cardiomyocytes and Purkinje Neurons in Response to Irradiation but Not in Steady State.. Blood, 2004, 104, 3604-3604. | 1.4 | 0 |
| 111 | Long-term striatal overexpression of GDNF selectively downregulates tyrosine hydroxylase in the intact nigrostriatal dopamine system. European Journal of Neuroscience, 2003, 17, 260-270. | 2.6 | 114 |
| 112 | Anterograde delivery of brainâ€derived neurotrophic factor to striatum via nigral transduction of recombinant adenoâ€associated virus increases neuronal death but promotes neurogenic response following stroke. European Journal of Neuroscience, 2003, 17, 2667-2678. | 2.6 | 56 |
| 113 | Elevated GDNF levels following viral vector-mediated gene transfer can increase neuronal death after stroke in rats. Neurobiology of Disease, 2003, 14, 542-556. | 4.4 | 58 |
| 114 | Recombinant adeno-associated viral vector (rAAV) delivery of GDNF provides protection against 6-OHDA lesion in the common marmoset monkey (Callithrix jacchus). Experimental Neurology, 2003, 184, 536-548. | 4.1 | 94 |
| 115 | Modeling CNS neurodegeneration by overexpression of disease-causing proteins using viral vectors. Trends in Neurosciences, 2003, 26, 386-392. | 8.6 | 96 |
| 116 | Nigrostriatal Â-synucleinopathy induced by viral vector-mediated overexpression of human Â-synuclein: A new primate model of Parkinson's disease. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 2884-2889. | 7.1 | 382 |
| 117 | Reversal of motor impairments in parkinsonian rats by continuous intrastriatal delivery of <scp>l</scp> -dopa using rAAV-mediated gene transfer. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 4708-4713. | 7.1 | 137 |
| 118 | Neuroprotection in the rat Parkinson model by intrastriatal GDNF gene transfer using a lentiviral vector. NeuroReport, 2002, 13, 75-82. | 1.2 | 123 |
| 119 | Parkinson-Like Neurodegeneration Induced by Targeted Overexpression of Î±-Synuclein in the Nigrostriatal System. Journal of Neuroscience, 2002, 22, 2780-2791. | 3.6 | 633 |
| 120 | l-DOPA-Induced Dyskinesia in the Intrastriatal 6-Hydroxydopamine Model of Parkinson's Disease: Relation to Motor and Cellular Parameters of Nigrostriatal Function. Neurobiology of Disease, 2002, 10, 165-186. | 4.4 | 378 |
| 121 | Neuronal replacement from endogenous precursors in the adult brain after stroke. Nature Medicine, 2002, 8, 963-970. | 30.7 | 2,613 |
| 122 | Growth and Functional Efficacy of Intrastriatal Nigral Transplants Depend on the Extent of Nigrostriatal Degeneration. Journal of Neuroscience, 2001, 21, 2889-2896. | 3.6 | 100 |
| 123 | Delayed infusion of GDNF promotes recovery of motor function in the partial lesion model of Parkinson's disease. European Journal of Neuroscience, 2001, 13, 1589-1599. | 2.6 | 115 |
| 124 | Preservation of a functional nigrostriatal dopamine pathway by GDNF in the intrastriatal 6-OHDA lesion model depends on the site of administration of the trophic factor. European Journal of Neuroscience, 2000, 12, 3871-3882. | 2.6 | 182 |
| 125 | Long-Term rAAV-Mediated Gene Transfer of GDNF in the Rat Parkinson's Model: Intrastriatal But Not Intranigral Transduction Promotes Functional Regeneration in the Lesioned Nigrostriatal System. Journal of Neuroscience, 2000, 20, 4686-4700. | 3.6 | 386 |
| 126 | Chapter 11 Transplantation in the rat model of Parkinson's disease: ectopic versus homotopic graft placement. Progress in Brain Research, 2000, 127, 233-265. | 1.4 | 85 |

| # | Article | IF | Citations |
|---|---|---|---|
| 127 | In Vivo Protection of Nigral Dopamine Neurons by Lentiviral Gene Transfer of the Novel GDNF-Family Member Neublastin/Artemin. Molecular and Cellular Neurosciences, 2000, 15, 199-214. | 2.2 | 134 |
| 128 | Protection and regeneration of nigral dopaminergic neurons by neurturin or GDNF in a partial lesion model of Parkinson's disease after administration into the striatum or the lateral ventricle. European Journal of Neuroscience, 1999, 11, 1554-1566. | 2.6 | 219 |
| 129 | Neurturin enhances the survival of intrastriatal fetal dopaminergic transplants. NeuroReport, 1999, 10, 1783-1887. | 1.2 | 40 |
| 130 | Neurturin Exerts Potent Actions on Survival and Function of Midbrain Dopaminergic Neurons. Journal of Neuroscience, 1998, 18, 4929-4937. | 3.6 | 308 |
| 131 | Acute Contractile Effects of Epidermal Growth Factor on Bladder Smooth Muscles: An <i>In Vivo</i> and <i>In Vitro</i> Study in Rats. Scandinavian Journal of Urology and Nephrology, 1997, 31, 231-235. | 1.4 | 5 |
| 132 | Studies on Neuroprotective and Regenerative Effects of GDNF in a Partial Lesion Model of Parkinson's Disease. Neurobiology of Disease, 1997, 4, 186-200. | 4.4 | 239 |